Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

3.

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR; ISIS 2302-CS9 Investigators.

Gut. 2002 Jul;51(1):30-6.

4.
5.

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.

Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G; German ICAM-1 Study Group.

Gastroenterology. 2001 May;120(6):1339-46.

PMID:
11313303
6.

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr.

Aliment Pharmacol Ther. 2006 May 15;23(10):1415-25.

7.

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr.

Gastroenterology. 1998 Jun;114(6):1133-42. Erratum in: Gastroenterology 2001 Sep;121(3):747.

PMID:
9609749
8.
9.

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.

Miner PB Jr, Wedel MK, Xia S, Baker BF.

Aliment Pharmacol Ther. 2006 May 15;23(10):1403-13. Erratum in: Aliment Pharmacol Ther. 2006 Oct 15;24(8):1268.

10.

Alicaforsen. Isis Pharmaceuticals.

Gewirtz AT, Sitaraman S.

Curr Opin Investig Drugs. 2001 Oct;2(10):1401-6. Review.

PMID:
11890355
11.
12.
13.
14.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.

Gastroenterology. 2007 May;132(5):1672-83. Epub 2007 Mar 21.

PMID:
17484865
15.

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.

Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):421-30.

16.

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84.

17.

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.

Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK.

Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34.

18.

Alicaforsen therapy in inflammatory bowel disease.

Barish CF.

Expert Opin Biol Ther. 2005 Oct;5(10):1387-91. Review.

PMID:
16197343
19.

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A.

Aliment Pharmacol Ther. 2006 Mar 1;23(5):617-28.

20.

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.

Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H.

Am J Gastroenterol. 2008 Sep;103(9):2284-92. doi: 10.1111/j.1572-0241.2008.02024.x. Epub 2008 Jul 30.

PMID:
18671816
Items per page

Supplemental Content

Write to the Help Desk